Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 178Lung Neoplasms 56Neoplasms 14NSCLC 11Brain Neoplasms 11Neoplasm Metastasis 10Carcinoma 9Meningeal Carcinomatosis 6Colorectal Neoplasms 5Bronchial Neoplasms 5Thoracic Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Prostatic Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumor × osimertinib × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Allist Pharmaceuticals, Inc.

Phase 1/2 Completed
58 enrolled
Other solid neoplasmThoracic

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡